∙ Individuals must meet all of the following criteria in order to be eligible for this study.

• Subject must be able to understand and provide informed consent.

• Male or female, 18 through 60 years old, inclusive, at the time of informed consent.

• Meet criteria for UNOS listing for lung transplantation.

• Patients must have evidence of end stage lung disease. Examples of such diseases include but are not limited to:

‣ Pulmonary Fibrosis

⁃ COPD/Emphysema

• Patients must have evidence of bone marrow failure with abnormal low cell count in at least one hematopoietic line, making the patient a poor candidate for long-term immunosuppressive therapy. Eligible patients must meet at least one of the following criteria:

‣ Unexplained, non-drug induced neutropenia with absolute neutrophils counts of \<1500/µL the previous year, confirmed by repeat testing

⁃ Unexplained, non-drug induced thrombocytopenia with mean platelets counts of \<100,000/µL the previous year, confirmed by repeat testing

⁃ Unexplained, non-hemolytic anemia, with a hemoglobin level of \< 12 g/dL the previous year, confirmed by repeat testing

• GFR ≥45 mL/min/1.73 m2.

• AST, ALT ≤4x upper limit of normal, total bilirubin ≤ 2.5 mg/dL, normal INR, albumin \>3.0 g/dL

• Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%.

• Negative pregnancy test for females, unless surgically sterilized.

⁃ All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defect.

⁃ Subject will also be counseled regarding the potential risks of infertility following BMT and advised to discuss sperm banking or oocyte harvesting.